Publications by authors named "E Arellano-Rodrigo"
Background: V617F-mutated myeloproliferative neoplasms (MPN) exhibit abnormal proliferation of bone marrow progenitors and increased risk of thrombosis, specifically in splanchnic veins (SVT). The contribution of the endothelium to the development of the prothrombotic phenotype was explored.
Material And Methods: Plasma and serum samples from V617F MPN patients with (n=26) or without (n=7) thrombotic debut and different treatments, were obtained (n=33).
Article Synopsis
- Hydroxyurea (HU) is the primary treatment for essential thrombocythemia (ET), but there are no clear guidelines for when to switch therapies.
- In a study of 1080 patients, 67% achieved a complete hematological response (CHR) after five years, with high-risk patients showing lower risks of arterial thrombosis if they achieved CHR.
- Patients with HU resistance or intolerance had a higher chance of developing myelofibrosis, but this did not significantly impact overall survival or thrombotic risk; CHR is linked to improved outcomes and may guide future treatment decisions.